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Introduction 
Study Design 
Development over Time 
Pregnancy Outcome 
Recurrent Pregnancy Loss (RPL) is the cause of childlessness in 2-5% of 
reproducing couples. Immunological mechanisms have been proposed as an 
etiology in some cases of RPL. Various forms of immunotherapy have been 
attempted in individuals thought to have an immunologic mechanism 
associated with RPL.  
Intravenous immunoglobulin (IvIg) has been tested in a placebo-controlled 
trial of women with RPL. In a blinded setup, some of the women were given 
treatment with intravenous immunoglubolin and the rest were given placebo 
(human albumin). Venous peripheral blood (EDTA) was obtained from the 
women at several time points during their pregnancy. 
 
Twelve women from the trial were included in this study, where 5 of the 
women were given treatment with IvIg. The effect on plasma sEV phenotypes 
and levels were investigated during the pregnancy using the protein 
microarray based EV Array analysis platform (Baek et al., 2017, Methods Mol 
Biol). In total 34 antibodies against surface-markers of interest were included. 
The first of the sequential samples (obtained before the first infusion in 
pregnancy week 5) from each woman were used as reference point to which 
the rest of the samples were normalized in order to detect the change over 
time.  
Already at the second sampling point (after 2-3 weeks) the level of small EVs 
(sEVs) carrying markers of interest increased massively (2-6 fold) in 3 of the 5 
women treated with IvIg. After 4-6 weeks, this increase stops and remains 
stable during the rest of the pregnancy.  
The highest increase were seen in sEVs carrying Placental Alkaline 
Phosphatase (PLAP) indicating that the newly produced sEVs originate from 
placenta. The level of sEVs positive for the two G-couple protein receptors 
Cholinergic Receptor Muscarinic 4 (CHRM4) and β-2 Adrenergic Receptor 
(ADRB2) showed the same increasing tendencies and it could be speculated, 
that the placenta had been activated by the treatment with IvIg to produce 
more of these receptors. 
This pilot study indicate that the level of sEVs in plasma are highly affected by 
treatment with IvIg, but a larger cohort is needed to verify these observations. 
To answer, if it is possible to predict the pregnancy outcome early in the 
pregnancy the level of sEVs were compared using data from the first drawn 
blood sample. The two women who suffered from spontaneous miscarriage 
had the lowest amount of sEVs, which were seen for all of the EV surface 
molecules that were analyzed. 
The women who gave birth showed already early in the pregnancy higher 
levels of sEVs carrying CD81, PLAP, HLA G, CHRM4 and ADRB2. 
Additionally, it seems that a high birth weight (above 4500 g) provides the 
highest levels of sEVs. 
A larger cohort/study is needed for increasing the statistical power. However, 
the tendencies are notably towards that the birth outcome can be predicted 
from the sEVs present in plasma early in the pregnancy. Hence, that it can be 
a signal to initiate a treatment to prevent spontaneous miscarriage. 
